Katz v. Organogenesis, Inc.

CourtDistrict Court, D. Massachusetts
DecidedSeptember 20, 2019
Docket1:17-cv-11595
StatusUnknown

This text of Katz v. Organogenesis, Inc. (Katz v. Organogenesis, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Katz v. Organogenesis, Inc., (D. Mass. 2019).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

SUSAN KATZ, * * Plaintiff, * * v. * Civil Action No. 17-cv-11595-ADB * ORGANOGENESIS, INC., * * Defendant. *

MEMORANDUM AND ORDER ON DEFENDANT’S MOTION FOR SUMMARY JUDGMENT

BURROUGHS, D.J. In this employment discrimination suit, Plaintiff Susan Katz alleges that her former employer, Defendant Organogenesis, Inc. (“Organogenesis”), discriminated against her in violation of federal and state law and terminated her based on her disabilities and her use of Family and Medical Leave Act (“FMLA”) leave. [ECF No. 1-1 (“Complaint” or “Compl.”)]. Currently pending before the Court is Organogenesis’ motion for summary judgment. [ECF No. 28]. For the reasons set forth below, summary judgment is GRANTED in favor of Organogenesis. I. BACKGROUND A. Factual Background The following facts are either uncontroverted pursuant to Federal Rule of Civil Procedure 56 and Local Rule 56.1 or stated in the light most favorable to Ms. Katz, the non-movant.1

1 The Court notes that while Ms. Katz purports to controvert portions of the Defendant’s Statement of Undisputed Facts (“SOF”), at times she fails to cite any record evidence in support of her position. Controverted facts must be supported by reference to record evidence. See LR, D. Mass 56.1 (“A party opposing the motion shall include a concise statement of the material facts of record as to which it is contended that there exists a genuine issue to be tried, with page Organogenesis is a pharmaceutical manufacturer that is subject to oversight by the Food & Drug Administration (“FDA”) and must comply with the FDA’s Current Good Manufacturing Practice regulations. [ECF No. 30 (“SOF”) ¶ 2]. Organogenesis works to comply with these regulations by ensuring that preventive maintenance tasks on its equipment are carried out in a

timely manner and according to standard operating procedures (“SOPs”). [SOF ¶ 3]. Preventative maintenance and calibration tasks are tracked using a computerized maintenance management system (“CMMS”). [SOF ¶¶ 5–6]. Staff must complete a written analysis of any error, referred to as “deviations,” such as a missed preventative maintenance task. [SOF ¶ 9]. If more than two related deviations occur, the standard practice is to initiate a “CAPA” (a “corrective action preventive action” or “corrective and preventive action”) to analyze the root cause. [SOF ¶ 10]. Ms. Katz was hired by Organogenesis in 2001 as a Facilities Coordinator to help administer the CMMS for preventive maintenance, which was known as “MP2.” [SOF ¶¶ 11– 12]. On March 13, 2006, Ms. Katz was promoted to Senior Facilities Coordinator, but her

responsibilities largely stayed the same. [SOF ¶¶ 13–14]. Ms. Katz took medical leave for a surgical procedure from September 27 to October 11, 2011, which did not adversely affect her employment. [SOF ¶¶ 30–31]. Ms. Katz’s work with the MP2 system resulted in positive job performance evaluations from her then-supervisors and a promotion in 2012 to Supervisor of Facilities Planning. [SOF ¶¶ 15–17, 31; ECF No. 32-1 at 9]. As Supervisor of Facilities Planning, Ms. Katz worked with the quality assurance department on audits, internal deviations,

references to affidavits, depositions and other documentation.”). The portions of the SOF not specifically controverted with support in the record are deemed admitted. See Caban Hernandez v. Philip Morris USA, Inc., 486 F.3d 1, 7 (1st Cir. 2007) (“In the event that a party opposing summary judgment fails to act in accordance with the rigors that [a local rule governing summary judgment] imposes, a district court is free, in the exercise of its sound discretion, to accept the moving party’s facts as stated.”). CAPAs, and SOPs. [SOF ¶ 18]. Her direct supervisor was the Facilities Manager, who was Mike Bukoff at the time of the promotion. [SOF ¶ 22]. Ms. Katz also supervised three direct reports: Brenda Lehan, a facilities coordinator; George Severance, a document specialist; and Marie Manning, a facilities associate. [SOF ¶¶ 19–21; ECF No. 32-1 at 14–15].

Between 2012 and early 2013, Organogenesis moved from the MP2 CMMS to a system called Regulatory Asset Manager (“RAM”). [SOF ¶ 23]. The RAM system was intended to replace both MP2, which tracked preventative maintenance management, and Calman, which tracked calibration management. [SOF ¶ 24]. The data from both systems was migrated into the RAM system. [SOF ¶ 24]. Ms. Katz was part of a team of approximately ten people that transitioned preventative maintenance management from MP2 to the RAM system. [SOF ¶ 27; ECF No. 35-1 at 5]. In 2013 or 2014, Ms. Katz began suffering from myofascial pain syndrome, a tightening of muscles that causes headaches, fatigue, and pain. [SOF ¶ 32].2 She took medical leave in May 2015 for three weeks for sinus surgery and used FMLA leave. [SOF ¶¶ 34–35]. This leave

did not adversely affect her employment. [SOF ¶ 36]. Near the beginning of 2015, a CAPA known as CAPA 15-007-DR (“the CAPA”) was opened to address numerous problems with the RAM system. [SOF ¶ 37]. Ms. Katz was involved with writing the CAPA and signed off on the action plan as the team leader. [SOF ¶¶ 38, 40; ECF No. 35-3 at 20 (noting that writing the CAPA was a “combined effort” of several employees)]. The CAPA concerned preventive maintenance records that were not correctly entered into the RAM system. [SOF ¶ 39]. The action plan for the CAPA included six tasks,

2 At some point, Ms. Katz was diagnosed with cervical dystonia, a condition causing neck pain, but this condition did not affect her ability to work. [SOF ¶ 33]. Ms. Katz has also been diagnosed and treated for depression since 2001. [SOF ¶ 29]. five of which listed either Ms. Katz alone or Ms. Katz and a subordinate or subordinates as those responsible for its completion. [SOF ¶ 41]. In August or September of 2015, Mr. Bukoff and Cheryl McManamin, who supervised Mr. Carmichael, the Calibration Manager, recommended promoting Mr. Carmichael to supervise

the preventive maintenance program. [SOF ¶ 43]. Shortly thereafter, from October 2015 to January 2016, Ms. Katz took medical leave due to her myofascial pain. [SOF ¶¶ 45, 60]. Ms. Katz sought, but did not receive, FMLA leave for her absence from work between October 2015 and January 2016. [SOF ¶¶ 50–55].3 Instead, Organogenesis approved a personal leave of absence, originally covering the dates October 20, 2015 to January 6, 2016. [SOF ¶ 55]. Ms. Katz returned to work on January 12, 2016. [SOF ¶ 60]. While Ms. Katz was on medical leave, Mr. Carmichael was put in charge of the CAPA. [SOF ¶ 46]. On January 13 and 14, 2016, an outside group, CAI Consulting, conducted a mock inspection of Organogenesis’ facilities maintenance and engineering functions in preparation for an upcoming audit. [SOF ¶ 61]. On January 18, 2016, CAI Consulting issued their report,

which identified several issues with the preventative maintenance program. [SOF ¶ 62]; see [SOF ¶¶ 63–66]. On February 9, 2016, an Organogenesis internal audit identified 14 issues with calibration and preventive maintenance records, ten of which were assigned to Ms. Katz for the completion of “confirmation, root cause, immediate action, risk assessment and action plan.” [SOF ¶ 74]. Following the internal audit, Mr. Bukoff was fired on February 22, 2016. [SOF ¶ 78]. A lead technician named Rocco Digirolamo was also fired that day. [SOF ¶ 79]. Mr. Bukoff was told that his termination was based at least in part on his failure to address issues

3 Ms. Katz also sought, and was denied, short-term disability benefits through Prudential, which she appealed with the help of Mr. Bukoff and Ms. McManamin. See [SOF ¶¶ 47–49].

Free access — add to your briefcase to read the full text and ask questions with AI

Related

McDonnell Douglas Corp. v. Green
411 U.S. 792 (Supreme Court, 1973)
Texas Department of Community Affairs v. Burdine
450 U.S. 248 (Supreme Court, 1981)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Hodgens v. General Dynamics Corp.
144 F.3d 151 (First Circuit, 1998)
Higgins v. New Balance Athletic Shoe, Inc.
194 F.3d 252 (First Circuit, 1999)
Carmona v. Toledo
215 F.3d 124 (First Circuit, 2000)
Gillen v. Fallon Ambulance Service, Inc.
283 F.3d 11 (First Circuit, 2002)
Cochran v. Quest Software, Inc.
328 F.3d 1 (First Circuit, 2003)
Rathbun v. Autozone, Inc.
361 F.3d 62 (First Circuit, 2004)
Calero-Cerezo v. U.S. Dep of Justice
355 F.3d 6 (First Circuit, 2004)
Cabán Hernández v. Philip Morris USA, Inc.
486 F.3d 1 (First Circuit, 2007)
Sher v. U.S. Department of Veterans Affairs
488 F.3d 489 (First Circuit, 2007)
Tobin v. Liberty Mutual Insurance
553 F.3d 121 (First Circuit, 2009)
Hannon v. Beard
645 F.3d 45 (First Circuit, 2011)
Samuel Mesnick v. General Electric Company
950 F.2d 816 (First Circuit, 1991)

Cite This Page — Counsel Stack

Bluebook (online)
Katz v. Organogenesis, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/katz-v-organogenesis-inc-mad-2019.